Biotalys sharpens EVOCA launch plans and cuts cash burn as it reports 2025 results
Belgian agtech company Biotalys said EVOCA moved ahead with key U.S. and European approvals while the group narrowed its portfolio and reported 8 million euros in year-end cash.
Belgian agtech company Biotalys has published its full-year 2025 results and outlined a tighter business plan for 2026. The release focuses less on headline accounting figures and more on regulatory progress for its lead biocontrol products and a more disciplined operating model. Biotalys said it ended 2025 with 8 million euros in cash and cash equivalents, which it estimates gives it runway until the end of May 2026, while financing talks with investors are already well advanced.
The main product milestone was final U.S. Environmental Protection Agency approval for EVOCA, the company’s first candidate biofungicide moving toward commercialization. EVOCA is aimed at controlling Botrytis, or gray mold, and powdery mildew in fruit and vegetable production. In April 2026, the product also secured state registration in Florida, which Biotalys described as the first approval of an AGROBODY biocontrol by a U.S. state.
The European regulatory track also moved forward. During 2025, the Dutch regulator CTGB recommended approval of EVOCA’s active ingredient across the European Union, while the Dutch public health institute RIVM said there were no critical areas of concern and proposed low-risk classification. Biotalys added that EFSA has already opened a two-month public consultation on the dossier. For European horticulture, that means the company is trying to advance the same product through both the U.S. and EU approval systems at the same time.
Biotalys is also restructuring the business. After announcing a strategic refocus in February 2026, the board confirmed a streamlined operating model and the suspension of some early-stage activities. The company says that move should materially reduce cash burn through the end of 2028. Resources are being concentrated on commercial preparation for EVOCA NG and on BioFun-6, a second biofungicide candidate targeting Botrytis and powdery mildew in high-value fruits and vegetables.
The update also included technical progress on BioFun-6. Biotalys said initial field trials in Europe and the United States showed the product could match EVOCA’s performance at significantly lower dosage rates. The company also pointed to its AgroFresh partnership in the post-harvest market and continued work on BioIns-2 with Syngenta Crop Protection. For the crop protection market, the message is that Biotalys is trying to push protein-based biocontrols into premium fruit and vegetable segments while urgently securing the financing needed to reach the next commercial phase.